Decreased drug penetration in inflamed tissue related to changed mucosal metabolism in experimental colitis

Journal of Pharmaceutical Sciences

Volumn 96, Issue 8, 2007, Pages 2145-2153

  Pellequer, Yann ^a   Weissenborn, Verena ^a   Lamprecht, Alf ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Colitis; Cytochrome P450 3A; Drug targeting; Inflammatory bowel disease; Tissue penetration

Indexed keywords

AMIODARONE; CARBOXYFLUORESCEIN; CYTOCHROME P450 3A; GLYCOPROTEIN P; MYELOPEROXIDASE; RH 123; RHODAMINE 123; TACROLIMUS; TESTOSTERONE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DEGRADATION; DRUG EFFECT; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG TISSUE LEVEL; ENTERITIS; ENZYME ACTIVITY; MALE; MICROSOME; NONHUMAN; PROTEIN EXPRESSION; RAT;

EID: 34548010039     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20826     Document Type: Article

References (26)

1. Egan LJ, Sandborn WJ. 1998. Drug therapy of inflammatory bowel disease. Drugs Today 34:431-446.
2. Lamprecht A, Stallmach A, Kawashima Y, Lehr CM. 2002. Carrier systems for the treatment of inflammatory bowel disease. Drugs Future 27:961-971.
3. Fries W, Mazzon E, Squarzoni S, Martin A, Martines D, Micali A, Sturniolo GC, Citi S, Longo G. 1999. Experimental colitis increases small intestine permeability in the rat. Lab Invest 79:49-57.
4. Howden CW, Robertson C, Duncan A, Morris AJ, Russell RI. 1991. Comparison of different measurements of intestinal permeability in inflammatory bowel disease. Am J Gastroenterol 86:1445-1449.
5. Teahon K, Somasundaram S, Smith T, Menzies I, Bjarnason I. 1996. Assessing the site of increased intestinal permeability in coeliac and inflammatory bowel disease. Gut 38:864-869.
6. Siccardi D, Turner JR, Mrsny RJ. 2005. Regulation of intestinal epithelial function: A link between opportunities for macromolecular drug delivery and inflammatory bowel disease. Adv Drug Deliv Rev 57:219-235.
7. Farrell RJ, Murphy A, Long A, Donnelly S, Cherikuri A, O'Toole D, Mahmud N, Keeling PW, Weir DG, Kelleher D. 2000. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 118:279-288.
8. Farrell RJ, Kelleher D. 2003. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 178:339-346.
9. Lennernäs H. 1998. Human intestinal permeability. J Pharm Sci 87:403-410.
10. Erkoc FU, Ozsar S, Guven B, Kalkandelen G, Ugrar E. 1989. High-performance liquid chromatographic analysis of steroid hormones. J Chromatogr Sci 27:86-90.
11. Akashi T, Nefuji T, Yoshida M, Hosoda J. 1996. Quantitative determination of tautomeric FK506 by reversed-phase liquid chromatography. J Pharm Biomed Anal 14:339-346.
12. Cotreau MM, von Moltke LL, Beinfeld MC, Greenblatt DJ. 2000. Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level. J Pharmacol Toxicol Methods 43:41-54.
13. Bonkovsky HL, Hauri HP, Marti U, Gasser R, Meyer UA. 1985. Cytochrome P450 of small intestinal epithelial cells. Immunochemical characterization of the increase in cytochrome P450 caused by phenobarbital. Gastroenterology 88:458-467.
14. Schenkman JB, Cinti DL. 1978. Preparation of microsomes with calcium. Methods Enzymol 52:83-89.
15. Brunner LJ, Bennett WM, Koop DR. 1996. Selective suppression of rat hepatic microsomal activity during chronic cyclosporine nephrotoxicity. J Pharmacol Exp Ther 277:1710-1718.
16. Goriya HV, Kalia A, Bhavsar SK, Joshi CG, Rank DN, Thaker AM. 2005. Comparative evaluation of phenobarbital-induced CYP3A and CYP2H1 gene expression by quantitative RT-PCR in Bantam, Bantamized White Leghorn and White Leghorn chicks. J Vet Sci 6:279-285.
17. Krawisz JE, Sharon P, Stenson WF. 1984. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology 87:1344-1350.
18. Eade OE, Andre-Ukena SS, Moulton C, MacPherson B, Beeken WL. 1980. Lymphocyte subpopulations of intestinal mucosa in inflammatory bowel disease. Gut 21:675-682.
19. Stärkel P, Sempoux C, Van Den Berge V, Stevens M, De Saeger C, Desager JP, Horsmans Y. 1999. CYP 3A proteins are expressed in human neutrophils and lymphocytes but are not induced by rifampicin. Life Sci 64:643-653.
20. Borst P, Schinkel AH, Smit JJ, Wagenaar E, Van Deemter L, Smith AJ, Eijdems EW, Baas F, Zaman GJ. 1993. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther 60:289-299.
21. de Waziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune PH. 1990. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 253:387-394.
22. Hashimoto Y, Sasa H, Shimomura M, Inui K. 1998. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Pharm Res 15:1609-1613.
23. Weidenbach H, Leiz S, Nussler AK, Dikopoulos N, Bachem M, Buttenschoen K, Reinshagen M, Beger HG, Adler G, Schmid RM. 2000. Disturbed bile secretion and cytochrome P450 function during the acute state of experimental colitis in rats. J Hepatol 32:708-717.
24. Sempoux C, Stärkel P, Stevens M, Van Den Berge V, Horsmans Y. 1999. Cytochrome P450 3A proteins are expressed in B lymphocytes but not in T lymphocytes. Pharmacogenetics 9:263-265.
25. Fiocchi C. 1998. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 115:182-205.
26. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol 11:648-656.